Standout Papers
Citation Impact
Citing Papers
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
2012 Standout
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1
2012 Science
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
2017
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
2013
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2010
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Predictability of Genetic Interactions from Functional Gene Modules
2017
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
2011
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
Target engagement imaging of PARP inhibitors in small-cell lung cancer
2018
Evidence that the Nijmegen breakage syndrome protein, an early sensor of double-strand DNA breaks (DSB), is involved in HIV-1 post-integration repair by recruiting the ataxia telangiectasia-mutated kinase in a process similar to, but distinct from, cellular DSB repair
2008
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
2011
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
2012
Genomic profiling of breast tumours in relation to BRCAabnormalities and phenotypes
2009
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
2012
Triple-Negative Breast Cancer
2010 Standout
The DNA-damage response in human biology and disease
2009 StandoutNature
Human cancers express mutator phenotypes: origin, consequences and targeting
2011
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
A view on drug resistance in cancer
2019 StandoutNature
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
BRCAness revisited
2016
PARP inhibitor combination therapy
2016
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Ovarian cancer
2014 Standout
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Olaparib: First Global Approval
2015
Using or abusing: viruses and the cellular DNA damage response
2007
Genetic Interactions in Cancer Progression and Treatment
2011
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Advances in using PARP inhibitors to treat cancer
2012
DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis
2006
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
2010
Immunogenicity of induced pluripotent stem cells
2011 StandoutNature
mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability
2017
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models
2015
PARP-2 Regulates SIRT1 Expression and Whole-Body Energy Expenditure
2011
Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
2011
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
DNA Damage, Aging, and Cancer
2009 Standout
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
Breast cancer genomes — form and function
2010
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
2010
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
2010
A review of PARP inhibitors: from bench to bedside
2010
The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling
2013
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
2010
The DNA damage response and cancer therapy
2012 Nature
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
2006
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
2011
Synthetic lethality: the road to novel therapies for breast cancer
2016
The PtdIns(3,4)P2 phosphatase INPP4A is a suppressor of excitotoxic neuronal death
2010 StandoutNatureNobel
Genomic instability and the selection of treatments for cancer
2009
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
2013
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
2018
Clonal evolution in cancer
2012 StandoutNature
Synthetic lethality and cancer
2017
The Hallmarks of Aging
2013 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
2012
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
PARP inhibition: PARP1 and beyond
2010
Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
2010
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
2010
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
2016
The cancer genome
2009 StandoutNature
Deconstructing the molecular portraits of breast cancer
2010
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
2011
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
2012
Genomic instability in breast cancer: Pathogenesis and clinical implications
2010
Cancer genomics: from discovery science to personalized medicine
2011
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
2009
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
2012
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
2016
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
2011
Practical Approach to Triple-Negative Breast Cancer
2017
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
2012
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Cancer Interception
2011 Nobel
Hereditary gynaecological malignancies: advances in screening and treatment
2012
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
2013
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
2012
Following the Path of the Virus: The Exploitation of Host DNA Repair Mechanisms by Retroviruses
2006
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
2010
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
2010
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
2013
Preventing Future Cancers by Testing Women With Ovarian Cancer forBRCAMutations
2009
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
2012 Standout
Spermidine in health and disease
2018 StandoutScience
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Intratumor Heterogeneity: Evolution through Space and Time
2012
Metabolic reprogramming and cancer progression
2020 StandoutScience
The DNA-damage response: new molecular insights and new approaches to cancer therapy
2009
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
2009
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
2006
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Direct Cellular Responses to Platinum-Induced DNA Damage
2007
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Works of Alan Lau being referenced
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2010
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2016
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
2009
Suppression of retroviral infection by the RAD52 DNA repair protein
2004
The overexpression of specialized DNA polymerases in cancer
2005
Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase
2005
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
2015
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
2012
Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells
2010
Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer
2009
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancerin vivo
2015
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
2008
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
2008
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
2008